Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 19/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.55 |
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4340494 | 0.86 | CHEK1 (0.59) | CHEK1KCNH2 | |
| SCHEMBL3075706 | 0.83 | CHEK1 (0.59) | CHEK1KCNH2JAK2JAK3 | |
| SCHEMBL4349296 | 0.83 | CHEK1 (0.80) | CHEK1KCNH2 | |
| SCHEMBL4349325 | 0.82 | CHEK1 (0.64) | CHEK1KCNH2 | |
| SCHEMBL4347178 | 0.81 | CHEK1 (1.00) | CHEK1KCNH2 | |
| SCHEMBL3079109 | 0.74 | CHEK1 (0.53) | CHEK1KCNH2JAK2JAK3 | |
| SCHEMBL4348134 | 0.73 | CHEK1 (0.48) | CHEK1KCNH2 | |
| SCHEMBL4357649 | 0.73 | CHEK1 (0.47) | CHEK1KCNH2 | |
| SCHEMBL4342847 | 0.72 | CHEK1 (0.47) | CHEK1KCNH2 | |
| SCHEMBL3070314 | 0.72 | CHEK1 (1.00) | CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | CHEK1 1/4885KCNH2 3112/4885JAK2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.